Preclinical Testing of SSA Compounds in a Model of Pancreatic Neuroendocrine Tumors to Optimize Scheduling and Drug Exposition Abstract #2081

Introduction: Somatostatin analogues (SSA) such as Octreotide and Lanreotide have demonstrated a significant benefit in Neuroendocrine Tumors, particularly in the well/moderately differentiated types. Nevertheless, there are still several aspects of SSA treatments that remain unsolved, such as drug exposition in patients and schedule optimization.
Aim(s): This study will evaluate diverse schedules and drug exposition protocols of SSA compounds in a transgenic mouse model of pancreatic NETs (pNETs).
Materials and methods: The transgenic model of pNETs (RIP1Tag2) will be used to test the efficacy of Octreotide and other SSA compounds and formulations at 1, 2 and 2.5 µg/kg/h by minipump infusion (Alzet pumps). Treatment will start at 12 weeks of age, when tumors are already fully formed.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD Oriol Casanovas

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2754 Somatostatin Analogs (SSA) in Patients with Symptomatic Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH)
Introduction: DIPNECH is characterized by a proliferation of pulmonary neuroendocrine cells and multifocal neuroendocrine tumorlets and/or tumors. Although usually indolent, DIPNECH can cause chronic cough and dyspnea. There is very limited information on treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr. Jonathan Strosberg
#2956 Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis
Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Marion Feuilly
#3048 Somatostatin Analogs or Active Surveillance in Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors
Introduction: Non-functioning (NF), sporadic pancreatic neuroendocrine tumors (pNETs) have usually an indolent behavior, but sometimes show an unpredictable aggressiveness. Surgery is the first-choice for localized tumors >2 cm. Unresectable or metastatic lesions expressing somatostatin receptors (SSTRs) are treated with Somatostatin analogs (SSAs). No evidence of SSAs efficacy exists in tumors ≤2 cm, for which active surveillance has been proposed.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: PhD Giovanni Schinzari
#3067 Somatostatin Analogs in Real‐World Practice for Patients with Metastatic Neuroendocrine Tumors: A Single Institution Experience in the Ouest of Algeria (CHU Oran)
Introduction: The efficacy of somatostatin analogs (SSAs) were clearly established trough pivotal trials as first‐line agents for neuroendocrine tumors (NETs), but their use in clinical practice is largely unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD, PhD Nadia Ameziane
#3034 Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is ≥ 10%?
Introduction: The antiproliferative effect of first-line long acting somatostatin analogs (SSA) in advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) was shown in the PROMID and the CLARINET trials. Efficacy data in pancreatic NETs (PanNETs) with Ki-67 ≥ 10% are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD Teresa Alonso Gordoa